A Randomized, Prospective, Open Label, Multicenter Study Assessing the Safety and Utility of IC2000 and SPY Fluorescence Imaging Systems in the Identification of Lymph Nodes During Lymphatic Mapping in Subjects With Breast Cancer
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Feb 2018
At a glance
- Drugs IC 2000 (Primary)
- Indications Breast cancer
- Focus Diagnostic use; Registrational
- Acronyms FILM-B
- Sponsors Novadaq Technologies
- 02 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Oct 2019.
- 02 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2019.
- 02 Feb 2018 Planned initiation date changed from 1 Sep 2017 to 1 Jun 2018.